Quick Takeaways
- INMB - Inmune Bio, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity -165%.
- Info
- Insider Trading
- Financials
Inmune Bio, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- INMB on Nasdaq
- Location
- Boca Raton, FL
- Fiscal year end
- 31 December
- Latest financial report
- 30 Mar 2026
What Changed
- Return On Equity YoY change: <span class="text-green-600">+36%</span>.
- Most recent SEC facts end date: 30 Mar 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-03-30) highlights Return On Equity -165.2%, Return On Assets -53.7%, and Operating Margin -61738.0%.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
29.3/100
Weak Confidence medium
Return On Equity
-165%
Metric score 0.0/100
Return On Assets
-54%
Metric score 0.0/100
Financial Health
- Current Ratio
- 3.55x
- Quick Ratio
- 3.48x
- Debt to Equity
- 0.04x
Strengths
Debt-to-equity
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Key metrics snapshot
Return On Equity
-165%
YoY: +36%
Industry median: -47% (n=217)
Return On Assets
-54%
YoY: +47%
Industry median: -45% (n=216)
Operating Margin
-61738%
YoY:
Industry median: -314% (n=94)
Current Ratio
3.55x
YoY: +13%
Industry median: 3.67x (n=218)
Quick Ratio
3.48x
YoY: +13%
Industry median: 2.63x (n=83)
Debt-to-equity
0.04x
YoY:
Industry median: 0.28x (n=202)
NetIncomeLoss YoY
-9.2%
YoY:
Industry median: -9.9% (n=211)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -165% | +36% |
| Return On Assets | -54% | +47% |
| Operating Margin | -61738% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 3.55x | +13% |
| Quick Ratio | 3.48x | +13% |
| Debt-to-equity | 0.04x |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| NetIncomeLoss YoY | -9.2% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 26,585,258 | +16% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY